SEHK:2616
SEHK:2616Biotechs

Why CStone Pharmaceuticals (SEHK:2616) Is Up 7.9% After GAVRETO NRDL Inclusion Approval In China

CStone Pharmaceuticals announced that its RET-targeted cancer therapy GAVRETO® (pralsetinib) has been approved for inclusion in China’s National Reimbursement Drug List, with reimbursement due to begin on 1 January 2026. This listing materially broadens patient access in China’s public healthcare system, potentially reinforcing CStone’s role as a key oncology player in Greater China. We’ll now examine how NRDL inclusion for GAVRETO shapes CStone’s investment narrative, particularly around...
SEHK:1211
SEHK:1211Auto

Is It Too Late To Consider BYD After Recent Rally And Cooling Sentiment?

If you are wondering whether BYD is still a smart buy at today’s price, or if the big gains are mostly behind it, this article will walk through what the current market is really pricing in. After a 14.4% gain year to date and a 46.5% climb over 3 years, the recent 2.0% pullback over the last month suggests sentiment is cooling a bit, but not necessarily the long term story. Investors have been reacting to a mix of headlines around global EV competition, shifting subsidies in China, and...
SEHK:9992
SEHK:9992Specialty Retail

Does Pop Mart (SEHK:9992) Have the Governance And Product Breadth To Sustain Its US Ambitions?

Pop Mart International Group recently faced renewed scrutiny after Black Friday as investors questioned the pace of its US expansion and its reliance on a narrow range of collectible toy products, while also monitoring how quickly new revenue streams are emerging. A separate announcement detailing the composition of Pop Mart’s board, including executive, non-executive and independent non-executive directors, put governance in focus and may influence how investors view the company’s ability...